A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

• Is confirmed HIV-uninfected based on negative HIV-1/HIV-2 test results

• Is a cisgender man, transgender woman (assigned male sex at birth), transgender man (assigned female sex at birth), or gender nonbinary person

• Has had condomless receptive anal sex in the 12 months prior to screening (notincluding sex occurring in a mutually monogamous relationship) and has at least 1 ofthe following: receptive anal sex with 2 or more partners in the 3 months prior toscreening (regardless of condom use), rectal or urethral gonorrhea or chlamydia orincident syphilis in the 6 months prior to screening, or any self-reported stimulantdrug use with sex in the 3 months prior to screening

• Weighs ≥35 kg

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

• Has hypersensitivity or other contraindication to any component of the studyinterventions

• Has evidence of acute or chronic hepatitis B infection

• Has a history of malignancy within 5 years of screening except for adequatelytreated basal cell or squamous cell skin cancer, or in situ anal or cervical cancers

• Has taken cabotegravir, lenacapavir, or any other long-acting HIV prevention productat any time

• Is receiving or is anticipated to require any prohibited therapies from 30 daysprior to Day 1 through the study duration

• Has received an HIV vaccine at any time (ie, through past participation in aninvestigational clinical study) or monoclonal antibodies to HIV within 12 monthsbefore Day 1

• Is expecting to donate eggs at any time during the study